drugset / Trial / NCT00889473

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

NCT00889473 ↗

Phase 2 Completed 42 enrolled 9 Meters Biopharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease

Timeline

Start
2009-04
Primary completion
2009-11
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Larazotide Peptide 1 mg —

Indications